Patient Reported Outcomes with UVA-1 Therapy for Treatment of Sclerosing Skin Diseases

Launched by UNIVERSITY OF UTAH · Jun 8, 2021

Keywords

ClinConnect Summary

Ultraviolet (UV) therapy has been used in dermatology for decades. UVA-1 phototherapy uses the longest wavelengths in the UV spectrum from 340-400 nm. It can penetrate the skin deeper than other types of phototherapy and target different cell types including fibroblasts. In sclerosing skin conditions UVA-1 appears to be superior to other forms of UV therapy. Medium-to-high dose UVA-1 also appears to be superior to low dose UVA-1 for sclerosing conditions.

Sclerosing skin diseases treated with UVA-1 include systemic sclerosis (SSc), morphea and sclerodermatous graft vs. host disease (GVHD)....

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Must be able to understand and provide written informed consent
• • Must have a diagnosis of systemic scleroderma with cutaneous sclerosis, morphea, or sclerodermatous Graft vs. host disease based on the presence of characteristic clinical findings
• • Age of at least 18-years-old
• • Ability to engage in 30 UVA-1 treatments in a maximum of 100 days.
• Exclusion criteria:
• • Inability to complete study visits
• • UV light therapy in the 4 weeks prior to entering the study
• • Commercial tanning in the 4 weeks prior to entering the study
• • Current pregnancy or planned pregnancy during the study period
• • History of intolerance to ultraviolet light
• • Any other condition that will disqualify the patient from the study in the opinion of the investigator